Effect of Glycated Albumin on Phenytoin Binding in Elderly Patients with Type II Diabetes Mellitus

Barbara A.P. Kostic, Keith M. Olsen, Gregory L. Kearns, Stephen F. Kemp

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We evaluated the effect of glycated albumin on phenytoin protein binding in 36 elderly (age range 63–94 yrs) patients with type II diabetes mellitus (DM) under diet management. Serum was spiked with 15 mg/L phenytoin and incubated. A serum ultrafiltrate was obtained from each sample for determining total and free phenytoin concentrations. Glycated hemoglobin was determined by boronate‐affinity chromatography, and glycated albumin was separated from nonglycated fractions with boronate‐agarose gel. Glycated hemoglobin in the study group ranged from 4.3–14.6% (mean 7.8 ± SD 2.1%) and glycated albumin ranged from 3.7–12.5% (7.4 ± SD 2.6%). We observed no correlation between glycated albumin and the percentage of free phenytoin (r2 = −0.14; p = 0.419). The concentration of nonglycated albumin ranged from 0.66‐4.28 g/dl (mean 3.45 ± 0.67 g/dl) and was calculated from measured total and glycated albumin concentrations. A correlation between the free fraction of phenytoin and nonglycated albumin was not demonstrated (r2 = 0.22, p = 0.22). In addition, a correlation was not observed between total glycated albumin and the free fraction of phenytoin (r2 = −0.095; p = 0.58). We conclude that elderly patients with type II DM under diet control do not have significant alterations in phenytoin protein binding. The use of total serum phenytoin levels therefore appears appropriate for determining phenytoin dosages in elderly patients with well controlled type II DM. 1990 Pharmacotherapy Publications Inc.

Original languageEnglish (US)
Pages (from-to)362-365
Number of pages4
JournalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume10
Issue number5
DOIs
StatePublished - Jan 1 1990

Fingerprint

Phenytoin
Type 2 Diabetes Mellitus
Glycosylated Hemoglobin A
Protein Binding
Albumins
Serum
Diet
glycosylated serum albumin
Publications
Chromatography
Gels
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effect of Glycated Albumin on Phenytoin Binding in Elderly Patients with Type II Diabetes Mellitus. / Kostic, Barbara A.P.; Olsen, Keith M.; Kearns, Gregory L.; Kemp, Stephen F.

In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 10, No. 5, 01.01.1990, p. 362-365.

Research output: Contribution to journalArticle

Kostic, Barbara A.P. ; Olsen, Keith M. ; Kearns, Gregory L. ; Kemp, Stephen F. / Effect of Glycated Albumin on Phenytoin Binding in Elderly Patients with Type II Diabetes Mellitus. In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1990 ; Vol. 10, No. 5. pp. 362-365.
@article{0a515610d703417d83df4927cfde1099,
title = "Effect of Glycated Albumin on Phenytoin Binding in Elderly Patients with Type II Diabetes Mellitus",
abstract = "We evaluated the effect of glycated albumin on phenytoin protein binding in 36 elderly (age range 63–94 yrs) patients with type II diabetes mellitus (DM) under diet management. Serum was spiked with 15 mg/L phenytoin and incubated. A serum ultrafiltrate was obtained from each sample for determining total and free phenytoin concentrations. Glycated hemoglobin was determined by boronate‐affinity chromatography, and glycated albumin was separated from nonglycated fractions with boronate‐agarose gel. Glycated hemoglobin in the study group ranged from 4.3–14.6{\%} (mean 7.8 ± SD 2.1{\%}) and glycated albumin ranged from 3.7–12.5{\%} (7.4 ± SD 2.6{\%}). We observed no correlation between glycated albumin and the percentage of free phenytoin (r2 = −0.14; p = 0.419). The concentration of nonglycated albumin ranged from 0.66‐4.28 g/dl (mean 3.45 ± 0.67 g/dl) and was calculated from measured total and glycated albumin concentrations. A correlation between the free fraction of phenytoin and nonglycated albumin was not demonstrated (r2 = 0.22, p = 0.22). In addition, a correlation was not observed between total glycated albumin and the free fraction of phenytoin (r2 = −0.095; p = 0.58). We conclude that elderly patients with type II DM under diet control do not have significant alterations in phenytoin protein binding. The use of total serum phenytoin levels therefore appears appropriate for determining phenytoin dosages in elderly patients with well controlled type II DM. 1990 Pharmacotherapy Publications Inc.",
author = "Kostic, {Barbara A.P.} and Olsen, {Keith M.} and Kearns, {Gregory L.} and Kemp, {Stephen F.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1002/j.1875-9114.1990.tb02596.x",
language = "English (US)",
volume = "10",
pages = "362--365",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of Glycated Albumin on Phenytoin Binding in Elderly Patients with Type II Diabetes Mellitus

AU - Kostic, Barbara A.P.

AU - Olsen, Keith M.

AU - Kearns, Gregory L.

AU - Kemp, Stephen F.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - We evaluated the effect of glycated albumin on phenytoin protein binding in 36 elderly (age range 63–94 yrs) patients with type II diabetes mellitus (DM) under diet management. Serum was spiked with 15 mg/L phenytoin and incubated. A serum ultrafiltrate was obtained from each sample for determining total and free phenytoin concentrations. Glycated hemoglobin was determined by boronate‐affinity chromatography, and glycated albumin was separated from nonglycated fractions with boronate‐agarose gel. Glycated hemoglobin in the study group ranged from 4.3–14.6% (mean 7.8 ± SD 2.1%) and glycated albumin ranged from 3.7–12.5% (7.4 ± SD 2.6%). We observed no correlation between glycated albumin and the percentage of free phenytoin (r2 = −0.14; p = 0.419). The concentration of nonglycated albumin ranged from 0.66‐4.28 g/dl (mean 3.45 ± 0.67 g/dl) and was calculated from measured total and glycated albumin concentrations. A correlation between the free fraction of phenytoin and nonglycated albumin was not demonstrated (r2 = 0.22, p = 0.22). In addition, a correlation was not observed between total glycated albumin and the free fraction of phenytoin (r2 = −0.095; p = 0.58). We conclude that elderly patients with type II DM under diet control do not have significant alterations in phenytoin protein binding. The use of total serum phenytoin levels therefore appears appropriate for determining phenytoin dosages in elderly patients with well controlled type II DM. 1990 Pharmacotherapy Publications Inc.

AB - We evaluated the effect of glycated albumin on phenytoin protein binding in 36 elderly (age range 63–94 yrs) patients with type II diabetes mellitus (DM) under diet management. Serum was spiked with 15 mg/L phenytoin and incubated. A serum ultrafiltrate was obtained from each sample for determining total and free phenytoin concentrations. Glycated hemoglobin was determined by boronate‐affinity chromatography, and glycated albumin was separated from nonglycated fractions with boronate‐agarose gel. Glycated hemoglobin in the study group ranged from 4.3–14.6% (mean 7.8 ± SD 2.1%) and glycated albumin ranged from 3.7–12.5% (7.4 ± SD 2.6%). We observed no correlation between glycated albumin and the percentage of free phenytoin (r2 = −0.14; p = 0.419). The concentration of nonglycated albumin ranged from 0.66‐4.28 g/dl (mean 3.45 ± 0.67 g/dl) and was calculated from measured total and glycated albumin concentrations. A correlation between the free fraction of phenytoin and nonglycated albumin was not demonstrated (r2 = 0.22, p = 0.22). In addition, a correlation was not observed between total glycated albumin and the free fraction of phenytoin (r2 = −0.095; p = 0.58). We conclude that elderly patients with type II DM under diet control do not have significant alterations in phenytoin protein binding. The use of total serum phenytoin levels therefore appears appropriate for determining phenytoin dosages in elderly patients with well controlled type II DM. 1990 Pharmacotherapy Publications Inc.

UR - http://www.scopus.com/inward/record.url?scp=0025010547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025010547&partnerID=8YFLogxK

U2 - 10.1002/j.1875-9114.1990.tb02596.x

DO - 10.1002/j.1875-9114.1990.tb02596.x

M3 - Article

C2 - 2235672

AN - SCOPUS:0025010547

VL - 10

SP - 362

EP - 365

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -